HERA: A randomized, three-arm, multicenter comparison of 1 year and 2 years of herceptin vs. no herceptin in women with HER2 positive primary breast cancer who have completed adjuvant chemotherapy

Study Chairs
IBCSG: Dr. Olivia Pagani - Mendrisio, Switzerland
BIG: Dr. Martine J. Piccart - Brussels, Belgium

Lead Trial Coordinator
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
December 2001

Date of Closure
June 20, 2005

Targeted Accrual
2730 patients

Final Accrual
5102 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login